SEATTLE, June 11, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the upcoming presentation of data highlighting PIXUVRI ® (pixantrone), the first approved treatment in the European Union for aggressive B-cell non-Hodgkin lymphoma (NHL) for adult patients who have failed 2 to 3 prior lines of therapy, and results from a pooled analysis of data from completed Phase 1 and 2 studies of pacritinib, a novel, oral JAK2/FLT3 inhibitor, at the 18 th Congress of the European Hematology Association (EHA) Annual Meeting, June 13-16, 2013 in Stockholm, Sweden.
"At EHA, we plan to present further analyses of the final safety and efficacy data from our EXTEND pivotal trial of PIXUVRI that we believe expand our understanding of the potential clinical benefit for patients with aggressive B-cell NHL who had received 2 to 3 prior regimens," said Jack Singer, M.D., Executive Vice President, Global Medical Affairs and Translational Medicine at CTI. "In addition, at EHA, results from a pooled integrated safety analysis from four Phase 1 and 2 clinical trials will be presented that quantify clinical toxicities of pacritinib, our novel, oral JAK2/FLT3 inhibitor currently being investigated in a Phase 3 clinical program."
Information regarding the EHA presentations is below. Full abstracts can be viewed at the EHA website.
Abstract Number: P310Poster Title: Pixantrone monotherapy in histologically confirmed, relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: Post-hoc analyses from a Phase 3 trialPresentation Date/Time/Location: Friday, June 14, 5:45 to 7:00 p.m. CEST, Poster HallFirst Author: Dr. Ruth Pettengell, St. George's Hospital, London, United KingdomAbstract Number: P278Poster Title: Safety overview of phase I-II studies of pacritinib, a non-myelosuppressive JAK2/FLT3 inhibitor, in patients with hematological malignanciesPresentation Date/Time/Location: Friday, June 14, 5:45 to 7:00 p.m. CEST, Poster Hall First Author: Dr. S. Verstovsek, MD Anderson Cancer Center, Houston, United States Abstract Number: P983Poster Title: Characterization of the pharmacokinetic and pharmacodynamic properties of pacritinib, a novel oral JAK2/FLT3 inhibitor, in patients with myelofibrosis, AML and lymphoma Presentation Date/Time/Location: Poster session, Saturday, June 15, 5:45 to 7:00 p.m. CEST, Poster HallFirst Author: Dr. Suliman Al-Fayoumi, Cell Therapeutics, Seattle, United States About PIXUVRI (pixantrone) PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties. Unlike related compounds, PIXUVRI forms stable DNA adducts and in preclinical models has superior anti-lymphoma activity compared to related compounds. PIXUVRI was structurally designed so that it cannot bind iron and perpetuate oxygen radical production or form a long-lived hydroxyl metabolite -- both of which are the putative mechanisms for anthracycline induced acute and chronic cardiotoxicity. These novel pharmacologic properties allow PIXUVRI to be administered to patients with near maximal lifetime exposure to anthracyclines without unacceptable rates of cardiotoxicity.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts